Results 91 to 100 of about 62,795 (319)

Spasmodic Dysphonia

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Spasmodic dysphonia is a laryngeal dystonia that can present as adductor, abductor, or mixed types, with or without tremor. The etiology is not understood fully. Comprehensive evaluation is required to establish the diagnosis. Treatments include voice therapy, medications, botulinum toxin injection, laryngeal surgery, deep brain stimulation ...
Aaron J. Jaworek, Robert T. Sataloff
wiley   +1 more source

UNUSUAL CLINICAL PRESENTATION OF RELAPSE IN PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA. [PDF]

open access: yesJournal of IMAB, 2015
Acute lymphoblastic leukemia is a disease, which is more common in children. We report a clinical case of a patient aged 25. Thirty-two months before his last admission in Hematology clinic, acute pre- B lymphoblastic leukemia had been diagnosed and ...
Vanya Slavcheva   +4 more
doaj   +1 more source

Dysregulated iron metabolism in polycythemia vera: etiology and consequences

open access: yesLeukemia, 2018
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm. Virtually all PV patients are iron deficient at presentation and/or during the course of their disease.
Y. Ginzburg   +5 more
semanticscholar   +1 more source

Cardiovascular Plasticity and Adaptation of High‐Altitude Birds and Mammals

open access: yesIntegrative Zoology, EarlyView.
This schematic depicts the cardiovascular adaptations of mammals and birds to high‐altitude hypoxia. It highlights key phenotypic changes in oxygen transport and cardiac responses, driven by molecular mechanisms including transcriptional regulation and genetic modifications.
Huishang She, Yanhua Qu
wiley   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

open access: yes, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M   +6 more
core  

Frequent Use of Fresh Frozen Plasma Is a Risk Factor for Venous Thrombosis in Extremely Low Birth Weight Infants: A Matched Case-control Study [PDF]

open access: yes, 2012
Percutaneously inserted central catheters (PICCs) are often used in neonatal medicine. Venous thrombosis (VT) is one of the complications associated with PICC use. According to some reports, fresh frozen plasma (FFP) may be a risk factor for VT.
Fujimura, Masanori   +3 more
core   +1 more source

Polycythemia vera treatment algorithm 2018

open access: yesBlood Cancer Journal, 2018
Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old.
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar   +1 more source

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post   +4 more
wiley   +1 more source

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

open access: yesBlood, 2014
Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF).
A. Tefferi   +17 more
semanticscholar   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

open access: yesBritish Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy